Abstract Library

#3055 Dynamics of Changes in Chromogranin A Concentration as a Prognostic Factor Radiopeptide Therapy in Neuroendocrine Tumours

Introduction: Chromogranin A (CgA) is a non-specific marker of neuroendocrine tumors (NET) and its significantly increased level is an unfavorable prognostic factor while the decrease in CgA during biotherapy with somatostatin analogs (SSA) correlates with the increase in profession free survival (PFS).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Sygula A, Jurecka-Lubieniecka B, Hasse-Lazar K, Michalik B, Ledwon A,

Keywords: CgA, PRRT, prognosis,

#3035 Large-Cell Neuroendocrine Carcinoma of the Lung in Elderly Patient: Case Report and Review of Literature

Introduction: Lung neuroendocrine tumors account for less than 25% of lung cancers.Which is a rare malignant tumor with an aggressive profile has often already affected lymph nodes at presentation and it is de novo metastatic in nearly 40% of cases.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Aliane H, Ghomari S,

Keywords: Large cell neuroendocrine carcinoma, Biopsy, Immunohistochemical staining, Chemosensitivity, Prognosis,

#2967 Longitudinal Changes in Plasma 5-Hydroxyindoleacetic Acid (5-HIAA) and Other Biomarkers during Treatment of Functional Midgut Neuroendocrine Tumours (NETs) with Lanreotide Autogel: CALM NET Study Results

Introduction: CALM-NET (EudraCT 2013-002194-22; NCT02075606) evaluated pre-treatment circulating tumour cell levels in patients with NETs as a predictor of response to lanreotide autogel (LAN).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Shah T, Caplin M, Khan M, Houchard A, Furnace M,

Keywords: neuroendocrine tumours, lanreotide, biomarkers,

#2941 Mixed Urothelial and Neuroendocrine Carcinoma of the Urinary Bladder: Case Report and Literature Review

Introduction: Neuroendocrine tumors (NETs) comprise <1% of all bladder tumors,characterized by poor prognosis. These tumors may be either pure or impure, intermixed with urothelial carcinoma. There is currently no therapeutic consensus. We report the case of primary impure neuroendocrine carcinoma (NEC).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Saidi M, Ghomari S,

Keywords: urinary bladder, mixed tumor, urothelial carcinoma, neuroendocrine carcinoma, chemotherapy, radiotherapy,

#2934 Vasostatin-1 Predicts Recurrence in Patients Submitted to Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)

Introduction: An association between preoperative Vasostatin-1 (VS-1) plasma level and pathological features of aggressiveness was previously reported in patients with surgically resected nonfunctioning (NF) PanNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Manzoni M, Muffatti F, Colombo B,

Keywords: pancreatic neuroendocrine tumors, biomarkers, chromogranin A, vasostatin 1, recurrence,